Fig. 24
Percentage cell viability of Con-AgNPs against HepG2 cell lines at different concentration, (a) Untreated, (b) Std control, Cisplatin, (c) 12.5 µg/mL, (d) 25 µg/mL, (e) 50 µg/mL, (f) 100 µg/mL, (g) 200 µg/mL.
Fig. 24 | Scientific Reports
Percentage cell viability of Con-AgNPs against HepG2 cell lines at different concentration, (a) Untreated, (b) Std control, Cisplatin, (c) 12.5 µg/mL, (d) 25 µg/mL, (e) 50 µg/mL, (f) 100 µg/mL, (g) 200 µg/mL.
